View Document Preview and Link Document Date: 2014-07-16 09:24:23 Open Document File Size: 1,18 MB Share Result on Facebook
City Washington DC / Brussels / / Company Programme Risk Additional / Pope Woodhead and Associates Ltd / / Continent America / Europe / / Country Japan / United States / / / Event FDA Phase / / Facility Capability building / / / IndustryTerm health technology / talent management / test tools / manufacturing standards / pre-approval medical devices / market access communications / score-card systems / healthcare / pharmaceutical / medicinal products / energy / learning management systems / healthcare professionals / healthcare consulting / medicinal product / pharmaceutical regulation / career portal / pharmaceutical products / development audit / drug products / weight reduction product / selection risk management / radioactive diagnostic imaging agent / / MedicalCondition hypersensitivity reactions / systemic lupus erythematosus / serious infections / opportunistic infections / disease / tumour / high disease activity / SLE / / Organization EU RMP / B-R / Committee for Medicinal Products for Human Use / Old Grammar School / European Medicines Agency / US Food and Drug Administration / European Union / EU Pharmacovigilance Risk Assessment Committee / / Person Andrew Hobbs / Stella Wooder / Richard Huckle / / / Position Director This edition / Physician / Consultant / Director Contact / Managing Director / / Product Ultrasone Edition 8 Headphone/Headset / HbA1c W3 Major / RL / W2 Injection / PE27 / / PublishedMedium Foreword / / Technology health technology / diagnostic imaging / development solutions Technology / drug development / / URL www.popewoodhead.com / http / SocialTag 
B i - a n n u a l n e w s l e t t e r f ro m P o p e Wo o d h e a d Edition 8 - Summer 2014 Benefit-risk analysis & reporting comes of age